XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial

[at noodls] – BERKELEY, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA) today announced the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hypertension) has demonstrated … more

View todays social media effects on XOMA

View the latest stocks trending across Twitter. Click to view dashboard